FDA And Medical Abortions – Healthcare

On January 3, 2023, the FDA amended its Risk Evaluation and
Mitigation Strategies program for mifepristone to allow pharmacies
to carry the prescription abortion medication mifepristone.
Mifepristone is used along with misoprostol in the medical abortion
process to end an intrauterine pregnancy through ten (10) weeks
gestation. Prior to this change in FDA policy, mifepristone could
only be dispensed by clinics, doctors and certain mail-order
pharmacies if the patient saw the prescribing provider in
person.

Under the new FDA policy, retail pharmacies may dispense
mifepristone if the pharmacy agrees to the FDA’s rules for
dispensing the medication. Specifically, pursuant to the rules,
health care providers must complete a Prescriber Agreement Form and
a Patient Agreement Form (signed by and provided to the patient),
wherein the risks are fully explained and reviewed by the patient.
The patient must also be provided with the mifepristone Medication
Guide (FDA-approved information for patients). Furthermore,
mifepristone must be dispensed under the supervision of a certified
prescriber, or a certified pharmacy on a prescription issued by a
certified prescriber; and the pharmacy dispensing mifepristone must
be certified as well (i.e. must have completed a Pharmacy Agreement
Form); and finally, if the pharmacy is shipping mifepristone, it
must use a shipping service that provides tracking information, and
it must ensure that the patient receives the medication in a timely
manner. See, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-about-mifepristone-medical-termination-pregnancy-through-ten-weeks-gestation

The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.